SG Americas Securities LLC Increases Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

SG Americas Securities LLC increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 43.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,498 shares of the company's stock after purchasing an additional 6,774 shares during the quarter. SG Americas Securities LLC's holdings in Harmony Biosciences were worth $774,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after purchasing an additional 436 shares during the last quarter. Mendota Financial Group LLC grew its stake in Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock worth $33,000 after acquiring an additional 965 shares in the last quarter. CWM LLC boosted its holdings in shares of Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company's stock valued at $59,000 after purchasing an additional 775 shares during the period. Quarry LP bought a new position in Harmony Biosciences in the second quarter worth approximately $62,000. Finally, Quantbot Technologies LP purchased a new position in Harmony Biosciences during the 3rd quarter worth $74,000. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Harmony Biosciences Price Performance

NASDAQ:HRMY traded up $0.72 during trading hours on Thursday, reaching $39.54. 377,781 shares of the company's stock were exchanged, compared to its average volume of 564,952. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The business's 50-day simple moving average is $35.20 and its two-hundred day simple moving average is $35.22. The company has a market capitalization of $2.26 billion, a P/E ratio of 18.74, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. The business had revenue of $186.00 million during the quarter, compared to analysts' expectations of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm's quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.63 EPS. Sell-side analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HRMY has been the subject of a number of research reports. Mizuho boosted their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday, October 10th. Needham & Company LLC reissued a "buy" rating and set a $52.00 target price on shares of Harmony Biosciences in a report on Monday, January 13th. Raymond James reaffirmed an "outperform" rating and issued a $40.00 price target on shares of Harmony Biosciences in a research note on Thursday, October 10th. Oppenheimer reiterated an "outperform" rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Finally, Cantor Fitzgerald boosted their target price on Harmony Biosciences from $51.00 to $58.00 and gave the stock an "overweight" rating in a report on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences presently has a consensus rating of "Buy" and an average price target of $55.00.

Insider Activity

In other news, CFO Sandip Kapadia sold 25,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total value of $774,228.09. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,452 shares of company stock worth $2,831,679. Company insiders own 30.80% of the company's stock.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.